会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Dihydrothiazine prodrugs of thiazolium agents
    • 噻唑类药物的二氢噻嗪前药
    • US07511036B2
    • 2009-03-31
    • US11390946
    • 2006-03-27
    • Emily ReinhardElliot Katten
    • Emily ReinhardElliot Katten
    • C07D279/12A61K31/54A61K31/541A61K31/426
    • C07D279/12
    • Provided are compounds of the formula (and pharmaceutically acceptable salts thereof): wherein: R is hydrogen, methyl, hydroxymethyl or α-hydroxyethyl; R1 and R2 are independently selected from hydrogen, C1-C6 alkyl, C1-C6 hydroxyalkyl, C3-C8 cycloalkyl, C1-C6 alkenyl, C1-C6 alkynyl, amino, monoalkylamino, dialkylaminoalkyl, and pyrrolidin-1-ylalkyl; and Y is selected from the group consisting of C1-C6 alkyl, substituted and unsubstituted aryl; with the provisos that: (a) if Y is aryl, then at least one of R1 and R2 is other than hydrogen, and (b) if R2 is hydrogen R1 is other than methyl. Also provided are pharmaceutical compositions containing the compounds, and methods for the preparation of the compounds. The compounds are useful, among other things, as prodrugs which can be converted under acidic conditions to thiazolium agents. The compounds can be administered to mammals, including humans, for treatment of various indications.
    • 本发明提供下式的化合物及其药学上可接受的盐:其中:R是氢,甲基,羟甲基或α-羟乙基; R 1和R 2独立地选自氢,C 1 -C 6烷基,C 1 -C 6羟基烷基,C 3 -C 8环烷基,C 1 -C 6烯基,C 1 -C 6炔基,氨基,单烷基氨基,二烷基氨基烷基和吡咯烷-1-基烷基; Y选自C1-C6烷基,取代和未取代的芳基; 条件是:(a)如果Y是芳基,则R 1和R 2中的至少一个不是氢,和(b)如果R 2是氢,则R 1不是甲基。 还提供含有这些化合物的药物组合物,以及制备化合物的方法。 所述化合物尤其可用作可在酸性条件下转化为噻唑鎓试剂的前药。 化合物可以施用于哺乳动物,包括人类,用于治疗各种适应症。
    • 3. 发明申请
    • Halogenated sulfonamide derivatives
    • 卤代磺酰胺衍生物
    • US20070213376A1
    • 2007-09-13
    • US11714008
    • 2007-03-05
    • Vrej JubianMathivanan PackiarajanEmily Reinhard
    • Vrej JubianMathivanan PackiarajanEmily Reinhard
    • A61K31/44
    • C07D417/04
    • This invention is directed to halogenated sulfonamide derivatives which are ligands at the NPY Y5 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject an amount of a compound of the subject invention. Furthermore, the present invention is directed to use of a compound of the invention for the manufacture of a medicament for treating a subject suffering from depression, anxiety or obesity.
    • 本发明涉及作为NPY Y5受体的配体的卤代磺酰胺衍生物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明还提供通过混合治疗有效量的本发明化合物和药学上可接受的载体制备的药物组合物。 本发明还提供了制备药物组合物的方法,其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。 本发明还提供了治疗患有抑郁症的受试者的方法,其包括给予受试者一定量的本发明化合物。 本发明还提供了治疗患有焦虑症的受试者的方法,其包括给予受试者一定量的本发明化合物。 本发明还提供了治疗患有肥胖症的受试者的方法,其包括给予受试者一定量的本发明化合物。 此外,本发明涉及本发明化合物在制备用于治疗患有抑郁,焦虑或肥胖的受试者的药物中的用途。
    • 5. 发明申请
    • Dihydrothiazine prodrugs of thiazolium agents
    • 噻唑类药物的二氢噻嗪前药
    • US20050014747A1
    • 2005-01-20
    • US10824848
    • 2004-04-15
    • Emily ReinhardElliot Katten
    • Emily ReinhardElliot Katten
    • A61P9/00A61P9/10A61P9/12A61P9/14C07D279/12A61K31/54A61K31/541
    • C07D279/12
    • Provided are compounds of the formula (and pharmaceutically acceptable salts thereof): wherein: R is hydrogen, methyl, hydroxymethyl or α-hydroxyethyl; R1 and R2 are independently selected from hydrogen, C1-C6 alkyl, C1-C6 hydroxyalkyl, C3-C8 cycloalkyl, C1-C6 alkenyl, C1-C6 alkynyl, amino, monoalkylamino, dialkylaminoalkyl, and pyrrolidin-1-ylalkyl; and Y is selected from the group consisting of C1-C6 alkyl, substituted and unsubstituted aryl; with the provisos that: (a) if Y is aryl, then at least one of R1 and R2 is other than hydrogen, and (b) if R2 is hydrogen R1 is other than methyl. Also provided are pharmaceutical compositions containing the compounds, and methods for the preparation of the compounds. The compounds are useful, among other things, as prodrugs which can be converted under acidic conditions to thiazolium agents. The compounds can be administered to mammals, including humans, for treatment of various indications.
    • 本发明提供下式的化合物及其药学上可接受的盐:其中:R是氢,甲基,羟甲基或α-羟乙基; R 1和R 2独立地选自氢,C 1 -C 6烷基,C 1 -C 6羟基烷基,C 3 -C 8环烷基,C 1 -C 6烯基,C 1 -C 6炔基,氨基,单烷基氨基,二烷基氨基烷基和吡咯烷-1 - 烷基; Y选自C1-C6烷基,取代和未取代的芳基; 条件是:(a)如果Y是芳基,则R 1和R 2中的至少一个不是氢,和(b)如果R 2是氢,则R 1不是 甲基。 还提供含有这些化合物的药物组合物,以及制备化合物的方法。 所述化合物尤其可用作可在酸性条件下转化为噻唑鎓试剂的前药。 化合物可以施用于哺乳动物,包括人类,用于治疗各种适应症。
    • 6. 发明申请
    • Dihydrothiazine prodrugs of thiazolium agents
    • 噻唑类药物的二氢噻嗪前药
    • US20070054901A1
    • 2007-03-08
    • US11390946
    • 2006-03-27
    • Emily ReinhardElliot Katten
    • Emily ReinhardElliot Katten
    • A61K31/54A61K31/541A61K31/426C07D279/12
    • C07D279/12
    • Provided are compounds of the formula (and pharmaceutically acceptable salts thereof): wherein: R is hydrogen, methyl, hydroxymethyl or α-hydroxyethyl; R1 and R2 are independently selected from hydrogen, C1-C6 alkyl, C1-C6 hydroxyalkyl, C3-C8 cycloalkyl, C1-C6 alkenyl, C1-C6 alkynyl, amino, monoalkylamino, dialkylaminoalkyl, and pyrrolidin-1-ylalkyl; and Y is selected from the group consisting of C1-C6 alkyl, substituted and unsubstituted aryl; with the provisos that: (a) if Y is aryl, then at least one of R1 and R2 is other than hydrogen, and (b) if R2 is hydrogen R1 is other than methyl. Also provided are pharmaceutical compositions containing the compounds, and methods for the preparation of the compounds. The compounds are useful, among other things, as prodrugs which can be converted under acidic conditions to thiazolium agents. The compounds can be administered to mammals, including humans, for treatment of various indications.
    • 本发明提供下式的化合物及其药学上可接受的盐:其中:R是氢,甲基,羟甲基或α-羟乙基; R 1和R 2独立地选自氢,C 1 -C 6烷基,C 1 -C 6烷基, C 1 -C 6 - 羟基烷基,C 3 -C 8环烷基,C 1 -C 3 - C 1 -C 6亚烷基,C 1 -C 6炔基,氨基,单烷基氨基,二烷基氨基烷基和吡咯烷-1-基烷基; 并且Y选自C 1 -C 6烷基,取代和未取代的芳基; 条件是:(a)如果Y是芳基,那么R 1和R 2中的至少一个不是氢,和(b)如果R SUP > 2 是氢R 1以外的是甲基。 还提供含有这些化合物的药物组合物,以及制备化合物的方法。 所述化合物尤其可用作可在酸性条件下转化为噻唑鎓试剂的前药。 化合物可以施用于哺乳动物,包括人类,用于治疗各种适应症。
    • 8. 发明申请
    • Alkyl sulfonamide derivatives
    • 烷基磺酰胺衍生物
    • US20060293341A1
    • 2006-12-28
    • US11472826
    • 2006-06-21
    • Vrej JubianMathivanan PackiarajanHermogenes JimenezEmily Reinhard
    • Vrej JubianMathivanan PackiarajanHermogenes JimenezEmily Reinhard
    • A61K31/497A61K31/4439C07D417/02
    • C07D417/04
    • This invention is directed to alkyl sulfonamide derivatives which are ligands at the NPY Y5 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject an amount of a compound of the subject invention.
    • 本发明涉及作为NPY Y5受体的配体的烷基磺酰胺衍生物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明还提供通过混合治疗有效量的本发明化合物和药学上可接受的载体制备的药物组合物。 本发明还提供了制备药物组合物的方法,其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。 本发明还提供了治疗患有抑郁症的受试者的方法,其包括给予受试者一定量的本发明化合物。 本发明还提供了治疗患有焦虑症的受试者的方法,其包括给予受试者一定量的本发明化合物。 本发明还提供了治疗患有肥胖症的受试者的方法,其包括给予受试者一定量的本发明化合物。